🏢 Company Intelligence
What They Do
Cross Country Healthcare (CCRN) is a workforce solutions and staffing firm primarily serving the U.S. healthcare sector, placing travel nurses, allied health professionals, and physicians at hospitals and clinics. Its technology layer includes a proprietary vendor management system (Intellify) and AI-driven matching, scheduling, and credentialing platforms that automate clinician placement at scale.
Why FSI Keeps Surfacing This Company
The signal pipeline is likely flagging CCRN on commercial momentum rather than carbon capture relevance — a pending take-private acquisition by Aya Healthcare at $18.61/share has driven sharp price appreciation and elevated trading activity. Note: the 'Carbon Capture' domain tag appears to be a misclassification, as CCRN has no material carbon capture technology exposure.
Recent Developments
In June 2025, Cross Country agreed to be acquired by Aya Healthcare in an all-cash deal valuing the company at roughly $615M, with closing expected in late 2025 pending regulatory and shareholder approvals. The company has continued investing in its Intellify VMS and AI-enabled workforce platforms to differentiate against MSP competitors amid a softening post-COVID travel nurse rate environment.
Key Risks
Primary risk is deal break — antitrust review, shareholder litigation, or financing issues could collapse the Aya transaction and reset the stock toward standalone fundamentals. Underlying business faces continued bill-rate compression, declining travel nurse demand normalization, and intense competition from larger staffing platforms and in-house hospital float pools.
🔗 Technology Domains
👁️
Showcase mode.
The top 2 companies per domain will remain free. Deeper features below — AI corpus interrogation, swap reasoning, Telegram alerts — will require Premium (£70/month).
Request early access →
🚀 Premium Features — Coming Soon
Premium subscribers will get AI interrogation of the full 56,000+ article corpus, real-time Telegram alerts when this company is flagged, swap proposals with full reasoning, and the complete signal history for CCRN. Subscriptions launching soon.
Request Early Access →
Not investment advice. Company intelligence is derived from publicly available data sources. It does not constitute personalised investment advice or a recommendation to buy, sell, or hold CCRN. Capital at risk. Always seek independent financial advice.